Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Camilo Molina

Neurological Surgery Saint Louis, MO Medical Doctor

NPI 1639440506 CMS profile 524021

12634 Olive Blvd, Dept Neurological Surgery, Saint Louis, MO 63141

Open in the dashboard

General payments

$412,033

557 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Camilo Molina of Saint Louis, MO is reported in the CMS Open Payments database as having received $412,033 across 557 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $113,653 94
2024 General $121,257 134
2023 General $73,125 94
2022 General $59,874 91
2021 General $29,845 51
2020 General $5,525 43
2019 General $8,753 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Camilo Molina
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Camilo Molina were reported at $113,653. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Camilo Molina Neurological Surgery median Middle half National median
2019 $8,753 $582 $138–$3,006 $163
2020 $5,525 $294 $76–$2,174 $114
2021 $29,845 $387 $105–$2,432 $132
2022 $59,874 $542 $139–$2,989 $149
2023 $73,125 $534 $145–$2,697 $160
2024 $121,257 $574 $155–$3,046 $164
2025 $113,653 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smaio SA $87,295 64 payments
  2. Baxter Healthcare $76,963 59 payments
  3. Stryker Corporation $49,413 69 payments
  4. Augmedics Inc. $42,156 53 payments
  5. SI-BONE, Inc. $26,417 27 payments
  6. Medical Device Business Services, Inc. $25,617 28 payments
  7. Kuros Biosciences USA, Inc $24,297 21 payments
  8. DeGen Medical, Inc. $10,314 16 payments
  9. DePuy Synthes Products, Inc. $9,994 13 payments
  10. NuVasive, Inc. $9,953 35 payments
  11. Other $49,615 172 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $294,502 57 payments
  2. Travel and Lodging $75,168 138 payments
  3. Food and Beverage $31,343 358 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,100 1 payment
  5. Education $1,667 1 payment
  6. Entertainment $224 1 payment
  7. Gift $30 1 payment
Products named General payments · program years 2019–2025
  1. Xvision $210,780 265 payments
  2. FLOSEAL Surgical Care $39,469 26 payments
  3. FLOSEAL Surgical Care $29,415 20 payments
  4. EVEREST SPINAL SYSTEM $28,274 12 payments
  5. IFUSE IMPLANT SYSTEM $25,718 15 payments
  6. MAGNETOS $22,413 14 payments
  7. NIAGARA LATERAL ACCESS SYSTEM $13,919 7 payments
  8. MESA SPINAL SYSTEM $13,114 2 payments
  9. XIA 3 $13,000 1 payment
  10. TRITANIUM $13,000 1 payment
  11. Other $74,610 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

757

Median for Neurosurgery: 83

Drug cost

$9,328

Median for Neurosurgery: $872

Branded share of claims

8.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 141 $2,038
Oxycodone Hcl Generic 152 $1,326
Pregabalin Generic 57 $1,220
Oxycontin Oxycodone Hcl Brand 17 $1,188
Mupirocin Generic 129 $894
Cyclobenzaprine Hcl Generic 58 $690
Methocarbamol Generic 36 $627
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $476
Amitriptyline Hcl Generic 39 $398
Baclofen Generic 12 $217

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 82 billing codes

Paid by Medicare

$312,870

Medicare's payments for the services billed

Medicare patients

195

Average age 70

Services billed

846

96 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 43%
Diabetes 34%
Ischemic heart disease 34%
Chronic kidney disease 29%
COPD 26%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

557 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record